Abbott Laboratories Gets Emergency Use Authorization for Covid-19/Flu Test

By Chris Wack

Abbott Laboratories said the U.S. Food and Drug Administration granted Emergency Use Authorization for its Alinity m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus in one test.

The company said the Alinity m Resp-4-Plex test can be conducted with one swab specimen self-collected at a healthcare location from individuals suspected by their provider of respiratory viral infection consistent with Covid-19.

Abbott said it has accelerated placements of the Alinity m system in hospital labs, academic centers and labs that are critical to patient care. This test is CE Marked and available in countries outside the U.S.

The company said the test will allow for fast and efficient diagnosis and triage of patients who present with respiratory symptoms.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

March 05, 2021 09:35 ET (14:35 GMT)

Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Aug 2024 to Sep 2024